期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

静脉免疫树突状细胞疫苗激活抗小鼠黑色素瘤CTL反应机制初探 被引量：3

A preliminary research on the mechanism of dendritic cell vaccines activate anti-melanoma CTL via intravenous injection
原文传递
导出
摘要 建立体外诱导分化骨髓来源树突状细胞(dendritic cell,DC)疫苗激活抗小鼠黑色素瘤CTL反应模型。体外分化小鼠骨髓来源树突状细胞并荷载鸡卵清白蛋白OVA257-264,静脉免疫小鼠1周之后接种表达OVA全长蛋白的小鼠黑色素瘤B16,观察成瘤情况并评价免疫效果。结果,体外分化小鼠骨髓来源树突状细胞并荷载OVA257-264肽段,表面表达肽段-主要组织相容性复合物(pMHC)作为第一信号以及共刺激分子CD80以及CD40;体内成瘤实验显示,静脉注射荷载OVA257-264能够抵抗B16-OVA的成瘤。DC疫苗静脉免疫后主要分布于肺部和脾脏。本研究通过静脉注射荷载OVA257-264肽段成熟DC,成功的诱导小鼠CTL免疫反应,抵抗黑色素瘤的成瘤。 To establish the bone marrow-derived dendritic cells（DC）vaccine in vitro to activate cytotoxic response in the mouse model of melanoma.Bone marrow-derived DCs were pulsed with OVA257-264 peptide.Mice were inoculated with B16-OVA cells one week after i.v.immunized with DCs.Tumorigenicity and immune effect was evaluated.Bone marrow derived DCs were loaded with OVA257-264 peptides.They expressed a high level of pMHC which serves as the first signal and expressed the costimulatory molecules,CD80 and CD40.In vivo experiments showed that mice were resistant to B16-OVA tumors by intravenous injection of peptide-loaded DCs which were mainly distributed in the lung and spleen.The immune response in melanoma tumorigenicity successfully arose via intravenous injection of OVA257-264-loaded mature DC prepared in vitro.This study successfully induced anti-melanoma CTL reaction by using the intravenous injection of OVA257-264-loaded DC vaccine.
作者 齐渊元 王雪 张晗 张立丽 聂红
机构地区 上海交通大学医学院上海市免疫学研究所
出处 《现代免疫学》 CAS CSCD 北大核心 2014年第6期492-496,共5页 Current Immunology
基金 国家自然科学基金面上项目(30872304) 上海市卫生局青年科研项目(2010Y017) 上海交通大学医学院基金(12XJ10005)
关键词 树突状细胞 DC疫苗 黑色素瘤 dendritic cell DC vaccines melanoma
分类号 R392.12 [医药卫生—免疫学]
  • 相关文献

参考文献2

二级参考文献19

  • 1[3]Steinman RM,Hawiger D,Liu K,et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance[J]. Ann NY Acad Sci, 2003,987:15.
  • 2[4]Hawiger D, Inaba K, Dorsett Y , et al. Dendritc cells induce peripheral T cell unresponsiveness under steady state conditions in vivo[J]. J Exp Med,2001,194:769.
  • 3[5]Liu K,lyoda T,Saternus M, et al. Immune Tolerance after delivery of dying cells to dendritic cells in situ[T]. J Exp Med,2002,196:1091.
  • 4[6]Bonifaz L, Bonnyay D, Mahnke K, et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance[J]. J Exp Med, 2002,196:1627.
  • 5[7]Jonuleit H, Schmitt E, Schuler G, et al. Induction of Interleukin 10-producing, nonproliterating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells [J]. J Exp Med,2000,192:1213.
  • 6[8]Mahnke K, Qian Y, Knop J, et al. Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells[J].Blood, 2003,101: 4862.
  • 7[9]Yamazaki S, lyoda T, Tarbell K, et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells [J]. J Exp Med,2003,198:235.
  • 8[10]Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells[J]. J Exp Med,2001,193:233.
  • 9[11]Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo in humans[J]. Blood,2002,100:174.
  • 10[12]Henri S,Vremee D, Kamath A, et al. The dendritic cell populations of mouse lymph nodes[J]. J Immunol,2001,167:741.

共引文献13

同被引文献46

  • 1赵辨.中国临床皮肤病学[M].南京:江苏科学技术出版社,2009,12:744.
  • 2Chaux P, Favre N, Martin M, et al. Tumor-infiltrating den- dritic cells are defective in their antigen-presenting function and inducible B7 expression in rats[J]. Int J Cancer, 1997, 72:619-624.
  • 3Steinman RM. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation[J]. Mt Sinai J Med, 2001,68:160-166.
  • 4Perrot I, Blanchard D, Freymond N, etal. Dendritic cells in- filtrating human non-small cell lung cancer are blocked at im- mature stage[J]. J Immunol, 2007,178 : 2763-2769.
  • 5Ali O A, Emerieh D, Dranoff G, et al. In situ regulation of DC subsets and T cells mediates tumor regression in mice[J]. Sci Transl Med, 2009,1:8-19.
  • 6Tuettenberg A, Huter E, Hubo M, etal. The role of ICOS in directing T cell responses:ICOS-dependent induction of T cell anergy by tolerogenic dendritic cells [J]. J Immunol, 2009,182 : 3349-3356.
  • 7Tian F, Wang L, Qin W, et al. Vaccination with transfor- ming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice[J]. Cancer Lett, 2008,271 : 333-341.
  • 8Nestle FO, Alijagic S, Gilliet M, etal. Vaccination of mela- noma patients with peptide- or tumor lysate-pulsed dendritic cells[J]. Nat Med, 1998,4:328-332.
  • 9Zhou Q, Munger ME, Veenstra RC, et al. Coexpression of Tim - 3 and PD - 1 identifies a CD8 + T - cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia [ J ]. Blood, 2011, 117(17) :4501 -4510.
  • 10Biswas MH, Du C,Zhang C, et al. Protein kinase D1 inhibits cell proliferation through matrix metalloproteinase -2 and matrix metal- loproteinase 70(5 ) :2095 9 secretion in prostate cancer[ J]. Cancer Res,2010 2104.

引证文献3

二级引证文献17

现代免疫学
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部